Current status of outcome measure development in vasculitis

Journal of Rheumatology

Volumn 41, Issue 3, 2014, Pages 593-598

  Merkel, Peter A ^a   Aydin, Sibel Z ^b,c   Boers, Maarten ^d   Cornell, Christina ^e   Direskeneli, Haner ^e   Gebhart, Don ^f   Hatemi, Gulen ^g   Luqmani, Raashid ^h   Matteson, Eric L ⁱ   Milman, Nataliya ^j   Robson, Joanna ^h   Seo, Philip ^k   Tomasson, Gunnar ^l  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^c GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g ISTANBUL UNIVERSITY   (Turkey)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ Mayo Clinic College of Medicine   (United States)

^j UNIVERSITY OF OTTAWA   (Canada)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l UNIVERSITY OF ICELAND   (Iceland)

more..

Author keywords

ASSESSMENT; OUTCOMES; VASCULITIS

Indexed keywords

ANCA ASSOCIATED VASCULITIS; ARTICLE; BEHCET DISEASE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTION; MEDICAL SOCIETY; MICROSCOPIC POLYANGIITIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME MEASUREMENT SYSTEM; PRIORITY JOURNAL; SHORT FORM 36; VASCULITIS DAMAGE INDEX AND COMBINED DAMAGE INDEX; WEGENER GRANULOMATOSIS;

ASSESSMENT; OUTCOMES; VASCULITIS;

HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; TREATMENT OUTCOME; VASCULITIS;

EID: 84895457101     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131248     Document Type: Article

References (26)

1. Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis - is it time to reclassify? Rheumatology 2011;50:643-5.
2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
3. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
4. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
5. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9. (Pubitemid 41117433)
6. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381-8.
7. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
8. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
9. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18. (Pubitemid 34525840)
10. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30. (Pubitemid 351650517)
11. Merkel PA, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, et al. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005;32:2488-95. (Pubitemid 41780676)
12. Seo P, Luqmani RA, Flossmann O, Hellmich B, Herlyn K, Hoffman GS, et al. The future of damage assessment in vasculitis. J Rheumatol 2007;34:1357-71. (Pubitemid 46898123)
13. Merkel PA, Herlyn K, Mahr AD, Neogi T, Seo P, Walsh M, et al. Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. J Rheumatol 2009;36:2362-8.
14. Direskeneli H, Aydin SZ, Kermani TA, Matteson EL, Boers M, Herlyn K, et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011;38:1471-9.
15. Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 2011;38:1480-6.
16. Herlyn K, Hellmich B, Seo P, Merkel PA. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res 2010;62:1639-45.
17. Seo P, Jayne D, Luqmani R, Merkel PA. Assessment of damage in vasculitis: expert ratings of damage. Rheumatology 2009;48:823-7.
18. Walsh M, Mukhtyar C, Mahr A, Herlyn K, Luqmani R, Merkel PA, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res 2011;63:1055-61.
19. Tomasson G, Boers M, Walsh M, LaValley M, Cuthbertson D, Carette S, et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res 2012;64:273-9.
20. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80. (Pubitemid 27114101)
21. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-20. (Pubitemid 32319784)
22. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
23. Bruyère SM, Van Looy SA, Peterson DB. The International Classification of Functioning, Disability and Health: Contemporary Literature Overview. Rehabil Psychol 2005;50:113-21. (Pubitemid 40770592)
24. Stucki G, Boonen A, Tugwell P, Cieza A, Boers M. The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. J Rheumatol 2007;34:600-6. (Pubitemid 46364018)
25. Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ, et al. Outcome measures used in clinical trials for Behçet's syndrome: a systematic review. J Rheumatol 2014;41:599-612.
26. Boers M, Kirwan J. How to choose core outcome sets for clinical trials: OMERACT 11 approves Filter 2.0. J Rheumatol 2014 (in press).